Neurodegeneration Biomarkers

From early pathological hallmarks to markers of neuroaxonal injury, biomarker analysis is an essential component of modern neurodegeneration research. Our expertise encompasses a broad range of molecular and histological endpoints across established preclinical models, providing valuable translational insights for drug discovery and development.

Mouse model of Alzheimer’s disease – transgenic strain ARTE10 (5 months)

Bar charts of the Aβ42/Aβ40 ratio in the hippocampus and cortex: higher in ARTE10 mice than in controls in both.

The results show a characteristic increase in Alzheimer’s disease in the ratio of amyloid beta 42 to 40 protein expression (structural elements of amyloid plaques) in brain structures in the model animal group compared to the control group.

Mouse model of Parkinson/Alzheimer – Tau P301L

Bar charts of the pTau/Tau ratio in the cortex, cerebellum and hippocampus: higher in Tau P301L mice than in wild type in all three.

The results show an increase in the ratio of phosphorylated tau protein to total tau protein present in the brain structures of animals with a modified tau protein gene compared to wild-type animals.

Mouse model of multiple sclerosis – EAE (experimental autoimmune encephalomyelitis)

Effect of neurodegeneration in plasma (NfL)
Bar chart of plasma NfL (pg/mL) for control, EAE, EAE + PR FGL and EAE + TH FGL mice: highest in the EAE group.

The results show an increase in plasma NfL in the group of animals with induced EAE compared to control animals, animals prophylactically administered fingolimod (PR FGL), and animals administered fingolimod after EAE induction – therapeutic effect (TH FGL).

Spinal Cord Demyelination
Mouse spinal cord sections stained with Luxol Fast Blue, two each for control, EAE, EAE + PR FGL and EAE + TH FGL, with arrows marking demyelinated regions.

Representative images of mouse spinal cord sections stained with Luxol Fast Blue, a widely used method for assessing myelin integrity, are shown. Black arrows highlight demyelinated regions, visible as bright, irregular areas against the blue-stained healthy tissue. These images demonstrate the ability to accurately identify and quantify myelin loss, supporting preclinical research in neurodegenerative and demyelinating diseases.

Key biomarker panels

  • NfL
  • Aβ42/Aβ40
  • GFAP
  • pTAU (Thr231)/Total TAU
  • S100B
  • MBP